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ABSTRACT 
Pyrimidines occupy an important position in the medicinal world as it has a number of diverse biological properties. Their related fused 
heterocycles are of interest as potential bioactive molecules. Pyrimidine derivatives are reported to have diverse pharmacological activities such as 
anticonvulsant, analgesic, sedative, anti-depressive, antipyretic, anti-inflammatory, antiviral, anti-HIV, antimicrobial and anti-tumor activities. 
Therefore, the study in this review has been emphasized on the research work reported in the recent scientific literature on different biological 
activities of pyrimidine analogs. 
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INTRODUCTION 
Pyrimidine pharmacophore is an important and integral part of DNA 
and RNA and play an essential role in several biological processes 
and also have considerable chemical and pharmacological utility as 
antibiotics, antibacterial, cardiovascular as well as agrochemical and 
veterinary product. These derivatives were found to possess a range 
of diverse activities such as anti-inflammatory and analgesic, 
antimicrobial, anti-avian influenza virus (H5N1), against herpes 
simplex virus type-1 (HSV-1) and hepatitis-A virus (HAV), serotonin 
5-HT6 receptor antagonist, anti-arrhythmic agents, etc. (fig. 1). 
Pyrimidine analogs have been already demonstrated as platelet 
aggregation inhibitors, antagonists, anti-conceptive and anti-
parkinsonism agents [1]. 
Pyrimidines occupy an outstanding position in organic and 
medicinal chemistry for their high biological activity. The pyrimidine 
core is a structural constituent of vital Biomolecules like DNA and of 
critically important drugs like Fluorouracil, Etravirine, Risperidone, 
Iclaprim, Avanafil, and Rosuvastatin [2] (table 1). 
 
.  
Fig. 1: Diverse biological importance of pyrimidines 
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Biological aspects 
Pyrimidines represent a broad class of compounds, which have 
received considerable attention due to their wide range of biological 
activities such as anti-inflammatory, COX inhibitor, anti-cancer, anti-
allergic, analgesic etc. [3]. Given below is a brief account related to 
various biological activities of pyrimidine derivatives. 
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Pyrimidines as anti-Alzheimer's agent 
Alzheimer’s disease (AD) is a neurodegenerative disorder, responsible 
for causing dementia in over 50% of all cases. Now a day, AD is a major 
public health issue and will apparently be the most important disease 
in developed/developing countries. Persistent efforts have been made 
in the last decade to determine the etiopathogenesis of the disease and 
to perform early diagnosis and therapeutic control of the disorder. 
Currently, there is no drug available that provides the specific solution 
for treating Alzheimer’s disease. The pharmacological treatment 
involves the use of two classes of drugs, the acetylcholinesterase 
inhibitors (AchEI) and the glutamate modulators [4]. 
Loidreau et al., 2013 synthesized two series of novel N-aryl-7-
methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-aryl-7-
methoxybenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues using 
microwaves via a Dimroth rearrangement. The synthesized 
compounds were tested in vitro to evaluate their inhibition potential 
on five different kinases-CDK5/p25 (cyclin-dependent kinase), 
CK1δ/ε (casein kinase 1), GSK3α/β (glycogen synthase kinase 3), 
DYRK1A (dual-specificity tyrosine phosphorylation regulated 
kinase) and CLK1 (cdc2-like kinase 1). Among all these compounds, 
the benzothieno[3,2-d]pyrimidine derivative 1 and 2 showed 
interesting inhibition at a sub-micromolar level and showed 
selectivity towards CLK1 and DYRK1A kinase [5]. A series of N-
arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and 
pyrazino analogues were designed, synthesized and characterized 
by Loidreau et al., 2012 via microwave-accelerated condensation 
and Dimroth rearrangement. The inhibitory potency of the final 
products was tested against five Ser/Thr kinases (CDK5/p25, 
CK1δ/ε, CK1δ/ε, DYRK1A and CLK1). N-aryl pyrido 
[3’,2’:4,5]thieno[3,2-d]pyrimidin-4-amine derivatives 3, 4 and 5 
were found to be potent inhibitors of CK1 and CLK1 kinases [6]. 
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Pyrimidines as anti-angiogenic agent 
Angiogenesis is the process of new blood vessels formation by 
creating new capillaries from existing vasculature and it is a normal 
process for organ development. When there is a malfunction in 
controlling mechanisms of angiogenesis, it may be involved in the 
development and evolution of various diseases such as rheumatoid 
arthritis, inflammation, ocular neovascularization, psoriasis, tumor 
growth, and metastasis. More than twenty different factors are 
involved in this process, one of which is vascular endothelial growth 
factors (VEGFs). The VEGF family includes VEGF-A (usually named 
VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and a structurally 
related molecule, Placental Growth Factor (PlGF) [7].  
Perspicace et al., 2013 designed, synthesized and biologically 
evaluated thieno pyrimidines for their VEGFR-2 inhibitor activity. 
Among all the synthesized compounds, 6 was estimated to be a lead 
compound as it inhibits VEGFR-2 and HUVEC at very low 
concentration. By in vitro studies, tartaric acid salt of compound 6 
(EC50=31nM) was proved to block angiogenesis by inhibiting 
endothelial cell tube formation induced by VEGF as compared to 
standard drug Sunitinib (EC50=645nM). Therefore, it may be used as a 









Pyrimidines as anti-cancer agent 
Cancer is life threatening disease, affecting more than six million 
people per year worldwide. Drastic changes in the lifestyle of humans 
have increased the risk of developing different types of cancers. The 
continuous effort has been put to identify molecules with anti-cancer 
properties from both natural and synthetic sources [8]. There are the 
different type of receptors which are involved in cancer progression 
like p21 Activated kinases (PAKs), MCF-7 kinase, PKCK2 kinase, JAK1-
3kinase, FLT1 kinase, FLT3-4 kinase, CHK1 kinase, Aurora-A kinase, 
MGC-803 kinase, EC-109 kinase, B16-F10 kinase, etc.  
1,2,3-Triazole–pyrimidine–urea derivatives were designed, 
synthesized and evaluated for anticancer activity against by Ma et al., 
2015. These synthesized compounds were tested against four cell 
lines: MGC-803, EC-109, MCF-7, and B16-F10. Almost all of the 
synthesized compounds showed moderate to potent activity against 
all the cancer cell lines. But compounds 7, 8 and 9 showed promising 
growth inhibition against B16-F10 (IC50 = 32 nM, 35 nM and 42 nM, 
respectively). Furthermore, flow cytometry study revealed that 
compound 7 induced the cellular apoptosis in a concentration-
dependent manner [9]. Qin et al., 2015 synthesized some of the 2,4-
diaminopyrimidine derivatives and tested them for their biological 
activities, including anti-proliferation, inhibition of Aurora kinases and 
cell cycle effects. All the synthesized compounds exhibited more 
potent cytotoxicity against tumor cell lines compared with the VX-680 
control. Compound 10 showed the highest cytotoxicity (IC50=0.5-4.0 
μM) and showed more than 35-fold more selectivity for Aurora A over 
Aurora B. Molecular docking analysis also revealed that this 
compound showed better interaction with Aurora-A both from the 
perspective of structure and energy. Furthermore, compound 10 
induced G2/M cell cycle arrest in HeLa cancer cell lines. Thus, these 
synthetic compounds have the potential for further development as 
selective Aurora A inhibitors for anticancer activity [10]. Jin et al., 2014 
designed, synthesized and characterized ethyl 2-(benzylidene)-7-
methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-
carboxylate derivatives. Compound 11 was identified as good inhibitor 
of PKCK2 with IC50 = 0.56 μM that is 2.2-fold more potent and selective 
than 4,5,6,7-tetrabromobenzotriazole (TBB) with IC50 = 1.24 μM. The 
Ki values of compound 11 and TBB for PKCK2 were 0.78 μM and 2.70 
μM, respectively. Therefore, compound 11 inhibited endogenous 
PKCK2 kinase and showed promising antiproliferative activity worthy 
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A class of novel 1,2,3-triazole-pyrimidine analogs was designed and 
synthesized by Ma et al., 2014 and also reported their anticancer 
activity against four cancer cell lines (MGC-803, EC-109, MCF-7, and 
B16-F10). Among the synthesized compounds, 12 showed the most 
excellent anticancer activity with IC50 = 1.42 to 6.52 mM. Further 
studies showed that compound 12 could inhibit the proliferation of 
EC-109 cancer cells by inducing apoptosis and arresting the cell 
cycle at G2/M phase [12]. Madadi et al., 2014 synthesized a library of 
substituted 5-((1-benzyl-1H-indol-3-yl) methylene)-1,3-dimethyl 
pyrimidine-2,4,6(1H,3H,5H)-triones. All the synthesized compounds 
were tested on 60 types of human tumor cell lines for their in vitro 
cell growth inhibition and cytotoxicity. Compounds 13, 14, 15 and 16 
were found highly potent anti-cancer agents against ovarian, renal 
and breast cancer cell lines. The 4-methoxy-N-benzyl analog (14) 
was reported as the most active compound against OVCAR-5 ovarian 
cancer cells and MDA-MB-468 breast cancer cells with GI50 =20 nM 
and 40 nM, respectively. While compounds, 13 and 16 were found 
equally potent (GI50 = 30 nM) against MDA-MB-468 cells. Against 
renal cancer cell line A498, compound 15 was found most potent 
(GI50 =40 nM). The study suggests that these compounds may act as 
lead for development of candidate drugs to treat a variety of solid 
tumors [8]. Temburnikar et al., 2014 synthesized halogenated thieno 
[3,2-d]pyrimidine derivatives and evaluated them in vitro for their 
anti-proliferative activity against three different cancer cell lines-
L1210 (a mouse lymphocytic leukemia cell line), CCRF-CEM (an 
acute lymphoblastic leukemia cell line), and HeLa (a cancer cell line 
derived from a human cervical adenocarcinoma). A structure-
activity relationship study indicated the presence of the chlorine at 
the C4-position is essential for anti-proliferative activity. The two 
most active compounds 17 and 18 were found to induce apoptosis in 
the leukemia L1210 cell line and found most active against all three 
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Abbas et al., 2013 designed, synthesized, characterized and 
evaluated two series of new tetrahydrobenzo [4,5] thieno [2,3-
d]pyrimidines namely 2,3-disubstituted derivatives and 2,4-
disubstituted ones for their antitumor potential. Compound 19 
showed excellent antitumor activity against breast MCF-7 (IC50 
=0.19 mM) compared to standard Doxorubicin (IC50 = 5.46 mM). 
Compound 20 was the most active one against liver HEPG-2 cancer 
cell line (IC50 =1.29 mM) as regard to Doxorubicin (IC50 =7.36 mM) 
[14]. Cheng et al., 2013 designed 4-methylpyridopyrimidinone series 
and tested for antitumor activity against PI3K, AKT, and mTOR 
kinases. Among them, compound 21 (PF-04691503) showed 
excellent in vitro potency and robust ADMET properties, and 
screened for in vivo antitumor efficacy model, and showed good 
tumor growth inhibition [15]. Analogs of pyrimidine-5-carbonitrile 
have been designed, synthesized and characterized by Fargualy et 
al., 2013. Among the synthesized compounds, selected members 
were evaluated for their anticancer activity against certain human 
tumor cell lines. The most active anticancer compounds found were 
22, 23, 24, 25 and 26. Among these, compounds 25 and 26 exhibited 
strong interactions with dihydrofolate reductase enzyme [16]. Lee et 
al., 2013 designed synthesized and characterized N-7-methyl-
imidazolopyrimidine derivatives. All the synthesized compounds 
were tested for their anticancer potential based on the hypothesis 
that the N-7-methyl substituent on imidazole pyrimidine would 
show selectivity for mTOR over the related PI3Kα and δ kinases. 
Among them, the pyrazolo [4,3-d]pyrimidine derivative 27 was 
found most potent compound [17]. Perspicace et al., 2013 designed, 
synthesized and evaluated a new class of thieno [3,2-d] 
pyrimidinone as an inhibitor of vascular endothelial growth factor 
receptor-2 (VEGFR-2). As predicted by the 3-D QSAR approach, 
compound 28 showed the highest activity and also biological assays 
on endothelial cell tube formation proved it as a new anti-angiogenic 
compound in inhibiting endothelial cell tube formation induced by 
VEGF compared with Sunitinib [7]. Xu et al., 2013 synthesized and 
evaluated a new series of 2-arylamino-4-aryl-pyrimidine derivatives 
for PAK1 kinase inhibitor anticancer properties in various colon 
cancer cell lines. Among them, compound 29 was found to be potent 
inhibitors of PAK1 kinase inhibitor. The kinase selectivity of 
compound 29 was investigated by screening against 81 of 118 
different kinases. Compound 29 showed strong inhibition of kinases 
JAK1-3, FLT1, FLT3-4, CHK1, and Aurora A, and therefore, 
compound 29 showed broad selective profile. The overall selectivity 
was determined by Gini coefficient = 0.40 for this molecule [18]. Wu 
et al., 2012 designed, synthesized a library of pyrido[2,3-
d]pyrimidine frameworks and tested for their c-Met inhibitory 
potency. Among the series, N-linked analogus demonstrated c-Met 
inhibitory potential. The 3-nitrobenzyl analog 30 showed the highest 
activity with IC50 value of 6.5 nM [19]. Two novel series of furo[2,3-
d]pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines 
were designed, synthesized and characterized by Jiao et al., 2012. 
Both the series were evaluated for their antiproliferative property. 
1,3-Dithiolane-substituted pyrazolopyrimidine 31was found to have 
potent in vitro ACK1 kinase inhibitor activity and displayed good 
kinase selectivity [20]. 
Pyrimidines as anti-convulsant agent 
Epilepsy is a neurological disorder characterized by an enduring 
predisposition to generate seizures due to abnormal neuronal 
activity in the brain. According to epidemiological studies, epilepsy 
is the third most devastating neurological disorder, and it affects 
more than 50 million people globally with most of these patients 
being in developing countries. Antiepileptic drugs (AEDs) 
comprise a diverse range of molecules acting mostly through: 
enhancement of γ-amino butyric acid (GABA) inhibitory 
neurotransmission, modulation of voltage-gated ion channels (Na+, 
Ca++), and reduction of excitatory, mainly glutamate-mediated 
neurotransmitter [21]. 
New substituted pyrimidine derivatives were designed, synthesized 
and characterized by Amr et al., 2005. All the synthesized 
compounds were screened for their anticonvulsant potential. 
Compound 32 was found most potent among all and showed even 
better activity than standard Carbamazepine with relative potency 
2.53. The ED50 was estimated which was found 11mg/kg. Thus, this 
cans beused as a lead in the search of safer and effective 
anticonvulsant agent. [21]. Wang et al., 2012 designed, synthesized 
and characterized a series of 5-alkoxytetrazolo [1,5-c] thieno [2,3-e] 
pyrimidine derivatives and estimated them for their anticonvulsant 
activity. Among the synthesized compounds (33, 34, 35 and 36) 
showed weak anticonvulsant activity [22]. 
Siddiqui et al. 

































































































R= C6H4(o-NH2)  , C6H4(m-NH2) , C6H5 , C6H4(p-Br)
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Pyrimidines as anti-diabetic agent 
Diabetes mellitus is known as a metabolic disorder caused by 
impaired secretion of insulin from pancreatic β-cells and is found 
one of the three leading causes of death worldwide. It is 
characterized by hyperglycemia resulting from defects in insulin 
secretion and/or insulin action. Hyperglycemia is associated with an 
alteration in lipid parameters which leads to cardiovascular 
complications [1]. GPR119 is a G-protein coupled receptor mainly 
acting on pancreatic beta cells and intestinal enteroendocrine cells. 
These GPR119 agonists such as oleoyl ethanolamine (OEA), 
lysophosphatidylcholine, N-oleoyl dopamine and olvanil were 
reported to stimulate glucose-dependent insulin secretion in vitro 
and lower increased blood glucose level in vivo [23]. Sodium-glucose 
cotransporters (SGLTs) inhibitors are a new approach to treat 
diabetes as their action of reducing blood glucose is insulin 
independent. By enhancing glucose excretion into urine, SGLT2 
inhibitors may lead to a considerable loss of calories [24]. Therefore, 
the ever-increasing disease burden from type 2 diabetes mellitus 
(T2DM) has encouraged sustained search for new therapies. 
Toobaei et al., [25] Designed, synthesized and evaluated poly-
hydroxyl functionalized acridine derivatives. These synthesized 
derivatives were tested for their inhibitory activities against α-
Glucosidase (α-Gls) and α–Amylase (α-Amy). Among the synthetic 
compounds, 37 with a chromeno [3’,4’:5,6] pyrido[2,3-d]pyrimidine 
moiety demonstrates the highest inhibitory activity against both 
yeast and rat α-Gls enzymes. Also, 38 with the thioxo-pyrido[2,3-d: 
6,5-d”] dipyrimidine moiety displays an important role in yeast α-
Gls inhibition. Therefore, 37 showed good inhibitory activity against 
α-Gls and a poor ability for inhibition of α-Amy and can be used as 
an important anti-diabetic agent for management of postprandial 
hyperglycemia [25]. Al-Harbi et. al., 2013 designed and synthesized 
a new class of poly-fused pyrazolothieno pyrimidine derivatives. All 
the synthesized compounds were tested for their hypoglycemic 
activities against standard pioglitazone (i. p., 5 mg/kg). All the 
synthesized compounds and the standard were found to have 
equipotent hypoglycemic activity (37.2±2.1-121.5±5.7). Compound 
39 was found to be potential hypoglycemic agent [1]. C-glucosides 
having a heteroaromatic ring were designed, synthesized and 
evaluated for their inhibitory activities against SGLT2 by Koga et al., 
2013 in high-fat diet fed KK (HF-KK) mice. Among the tested 
compounds, compound 40 was found to be very potent and selective 
inhibitor of hSGLT2. The anti-hyperglycemic effect was also 
observed in HF-KK mice for oral administration. Therefore, this 
compound can be a lead compound for the treatment of type II 
diabetes [24]. 
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5-Nitropyrimidine analogs substituted with conformationally 
restricted azabicyclic amines and alcohols were synthesized by Yang 
et al., 2013. All the synthesized compounds were screened for their 
agonistic activity against human GPR119 receptor in a cell-based 
cAMP assay. The analog 41 showed maximum agonistic activity 
(139% max) with slightly weak EC50 value (11.5 nM) [23]. Negoro et 
al., 2012 designed and synthesized a series of fused pyrimidine 
derivatives and evaluated them for their anti-diabetic property 
toward GPR119. The synthesized compounds were found to be 
potent and orally active GPR119 agonists. The 5,7-dihydrothieno 
[3,4-d] pyrimidine 6,6-dioxide derivative 42 was discovered as a 
highly potent agonist. Further replacement of the amino group at the 
4-position in the pyrimidine ring led to the discovery of an advanced 
analog 43. The compound 43 was found to be extremely potent 
agonistic activity and improved glucose tolerance at 0.1 mg/kg p. o. 
in mice. Hence, the compound 43 can be used for the treatment of 
type 2 diabetes mellitus [26]. Lee et al., 2005 designed and 
synthesized novel substituted pyrimidines having thiazolidinedione 
moiety. These synthesized compounds were evaluated for their 
glucose lowering property. By performing the antidiabetic activity, 
compounds 44 and 45 were found to be considerably more potent 
than that of the reference compounds, pioglitazone, and 
rosiglitazone, respectively [27].  
Pyrimidines as anti-hepatitis agent 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major 
reason of chronic liver diseases in humans. Co-infection with both 
HBV and HCV are common and associated with an increased risk of 
liver disease, cirrhosis and hepatocellular carcinoma that leads to 
mortality. Due to limitations of the current treatment, development 
of new agents is urgently required for both HBV and HCV [28]. HCV 
is an enveloped positive single stranded RNA virus that belongs to 
the family-Flaviviridae. Till date, a number of anti-HCV agents are 
being developed, mainly targeting the non-structural proteins, 
which still could fail in clinical trials due to severe side effects as 
described for the recently approved DAAs or because of rapid 
emergence of drug resistant mutants. This unpredictability and 
unmet medical needs encouraged us to connect with an HCV drug 
discovery campaign to develop new, safer and potent drugs against 
HCV with a high genetic barrier to resistance [29].  
Shakya et al., 2014 reported the synthesis and anti-HCV activity of 
the new class of pyrimidine nucleosides possessing a 40-
carboxymethyl and 40-carboxamide functional group. Among them, 
some of the compounds were found good anti-HCV agents without 
any toxicity. The results indicated that anti-HCV activities 
demonstrated by these compounds were superior to that of ribavirin 
(EC50 = 81.9 μM). Among the entirely synthesized compound, 46 was 
found the most active analog that interact synergistically with 
ribavirin to inhibit replication of HCV RNA [28]. 
Shakya et al., 2012 synthesized a new class of dideoxy pyrimidine 
nucleosides as potential antiviral agents. The cytotoxicity of the 
synthesized compounds was tested in the parental human hepatoma 
cell line (Huh-7) by XTT assay. These nucleosides were reported to 
be inhibitors of HBV and/or HCV replication. Among them, 30,40-
dide hydro thymidine (47) was reported as most effective against 
DHBV, HBV, and HCV. Compound 48 was not found effective against 
the anti-HBV activity but increased the anti-HCV activity and showed 
a synergistic antiviral effect when combined with ribavirin without 
toxicity. The compounds 49, 50 were also found to inhibit both HBV 
and HCV replication [30]. A series of 7-aminopyrazolo [1,5-
a]pyrimidines (7-APPs) were reported as a potent hepatitis C virus 
(HCV) inhibitor by Hwang et al., 2012. A group of 7-APPs was 
synthesized and screened them for inhibitory activity against HCV in 
different cell culture systems. The synthesized series of compounds 
were found to inhibit HCV life cycle. Compounds 51 and 52 showed 
good inhibitory activity against HCV and also showed low 
cytotoxicity with high selectivity index values (SI = 21 and 25, 
respectively) [29]. 
Pyrimidines as anti-inflammatory agent  
Inflammation is a characteristic of many diseases, and the 
persistence of this course may lead to various diseases like sepsis, 
arthritis, atherosclerosis, diabetes and even cancer [31]. The over 
expression of TNF-α has been caught up in a number of serious 
inflammatory disorders such as rheumatoid arthritis, inflammatory 
bowel disease (IBD), and osteoarthritis and Crohns disease. TNF-α is 
a potent inducer of other pro-inflammatory cytokines such as IL-1, 
IL-6, and IL-8. Therefore, agents that inhibit TNF-α production can 
reduce the levels of these pro-inflammatory cytokines resulting in a 
drop of inflammation and prevention of further tissue destruction 
[32]. Toll-like receptors (TLRs) play a key role in the activation of 
the innate immune system in response to invading pathogens (e. g. 
viruses, bacteria and fungi). Signalling via TLRs results in the 
activation of IκB kinases (IKKs) which regulate transcriptional 
programmes required for the production of inflammatory mediators 
to combat the invading pathogens. The canonical IKKs activate NF-
κB leading to the production of pro-inflammatory cytokines while 
the IKK-related kinases, known as TANK-binding kinase 1 (TBK1) 
Siddiqui et al. 
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and IκB kinase epsilon (IKKε) catalyze the activation of interferon 
regulatory factor 3 (IRF3) [33]. 
Keche et al., 2012 synthesized a class of pyrimidine derivatives by 
the sequential Suzuki cross coupling, acid amination, and reduction. 
All the synthesized compounds were tested for their pro-
inflammatory cytokines activity like TNF-α and IL-6. Among all the 
compounds evaluated, compounds 53, 54, 55, 56, 57 and 58 were 
found to be potent anti-inflammatory agents. They showed up to 48–
78% TNF-α and 56–96% IL-6 inhibitory activity with reference to 
standard dexamethasone at 10 μM [34]. Mclver et al., 2012 designed, 
synthesized and proposed structure–activity relationships of a novel 
series of 2,4-diamino-5-cyclopropyl pyrimidines and screened 
selected compounds for inhibition of LPS-induced RANTES release 
in cells. Among them, compound 59 showed a significant inhibition 
of LPS-induced release of the pro-inflammatory cytokine, IFN-β in 
mice. The chemical series has been proved useful suggesting that the 
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Pyrimidines as anti-malarial agent 
Malaria is caused by Plasmodium falciparum and it is a serious 
health problem in Africa, South America and many parts of Asia. The 
disease occurs in tropical Africa and the majorities are children 
under the age of five. The present therapies still believe in drugs that 
have been developed decades ago. The P. falciparum genome 
sequencing has revealed some new targets for drug and vaccine 
development. Development of newer antimalarial drugs only 
remains an economically and environmentally possible alternative 
to fighting out the menace of the disease [35]. 
Mane et al., 2012 synthesized a group of pyrido [1,2-a]pyrimidin-
4-ones and screened them for their in vitro FP-2 inhibitory 
potential. The studies described Plasmodium falciparum cysteine 
protease falcipain-2 (FP-2) as a promising target for antimalarial 
chemotherapy and proved that inhibition of this protease affects 
the growth of parasite adversely. It was found that compounds 60 
and 61exhibited excellent FP-2 inhibition and may serve as lead 
compounds for further investigation of potent FP-2 inhibitors as 
potential antimalarial drugs [35]. 4-Aminoquinoline pyrimidines 
were designed, synthesized and characterized by Singh et al., 
2013.  
All of the synthesized compounds were evaluated for their 
antimalarial potential. The findings showed that compound 62 was 
found most active (IC50 =156, 153 respectively) within the series 
against both CQS and CQR strains of P. falciparum respectively [36].  
Siddiqui et al. 
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Pyrimidines as anti-microbial agent 
In last decades, the prevalence of fungal and bacterial infections has 
increased dramatically. The universal use of antifungal and 
antibacterial drugs and their resistance against respective infections 
has led to serious health issues. The resistance to wide range of 
antifungal and antibacterial agents has initiated discovery and 
modification of the new antifungal and antibacterial drugs [37]. The 
rapid development of resistance to existing antimicrobial drugs 
poses a major threat to public health. Therefore, there is a pressing 
need to develop novel antimicrobial agents with potent activity 
against multidrug resistant microorganisms [38]. 
Desai et al., 2015 synthesized a series of 4-(4-(arylamino)-6-
(piperidin-1-yl)-1,3,5-triazine-2-ylamino)-N-(pyrimidin-2-yl) benzene 
sulfonamide analogs and evaluated them for their in vitro 
antimicrobial activity. Synthesized compounds were evaluated 
against Gram-positive bacteria [S. aureus (MTCC 96), S. pyogenes 
(MTCC 442)], Gram-negative bacteria [E. coli (MTCC 443), P. 
aeruginosa (MTCC 1688)] and fungal strains [C. albicans (MTCC 
227), A. niger (MTCC 282), A. clavatus (MTCC 1323)]. Compounds 
63, 64 and 65 exhibited significant antimicrobial activity on several 
strains of microbes [39]. Kanawade et al., 2013 designed some 
thermal selective reactions to synthesize a class of 4-aminothieno 
[2,3-d]pyrimidine-6-carbonitrile derivatives. These environmentally 
benign neat heat reactions gave products in good yield and in 
comparatively shorter time to conventional method. All the 
synthesized compounds were tested for their antimicrobial activity 
against several bacteria such as Staphylococcus aureus MTCC-96, 
Escherichia coli MTCC-443, Pseudomonas aeruginosa MTCC-4 41, 
Streptococcus pyogenes MTCC-442 and fungi Aspergillus niger 
MTCC-282, Aspergillus clavatus MTCC-1323, Candida albicans 
MTCC-227 using broth microdilution method. It was observed that 
compound 66, 67, 68, 69, 70 and 71 showed good antibacterial 
activity compared to standard ampicillin and compounds 69 and 70 
proved to be better antifungal agent compared to griseofulvin [40]. 
 Luo et al., 2013 synthesized some novel 1,3,4-thiadiazole 
derivatives bearing 1,2,4-triazolo[1,5-a]pyrimidine moiety. All the 
synthesized compounds were assayed for antimicrobial activities 
against five fungi strains (G. sanbinetti, F. oxysporum, P. piricola, R. 
solani and C. beticola) and four bacterial strains (B. subtilis, S. 
aureus, E. coli and P. fluorescence) by the serial dilution method. The 
results showed that Compound 71 demonstrate good antifungal 
activities against C. beticola and R. solani (Inhibition Rate = 89%). 
The compounds 72 showed the best antibacterial activity (MIC of 
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Pyrimidines as anti-oxidant agent 
The mitochondrial overproduction of superoxide radical plays an 
important role in activation of the other downstream path physiologic 
cycles which are involved in the further production of reactive oxygen 
species (ROS) [42]. Furthermore, pyrimidine derivatives have been 
proved as good antioxidants which can neutralize free radicals. Thus, 
antioxidants that forage reactive oxygen species may be of great 
value in preventing the onset and propagation of oxidative diseases 
such as autoimmune diseases, cardiovascular diseases, and 
neurovascular diseases and also show hypoglycemic and 
antibacterial properties. The homeostatic balance between the 
reactive oxygen species (ROS) and endogenous antioxidants is 
essential for maintaining healthy tissues [43]. Therefore, there is a 
need to develop new and safer antioxidant agents. Attri et al., 2014 
developed an efficient catalytic method to synthesize 3,4-dihydro 
pyrimidinones in high yield by one-pot three component Biginelli 
condensation in the presence of triethyl-ammonium acetate (TEAA) 
as catalyst/reaction medium. All the synthesized compounds were 
tested for their antioxidant property using 1,1-diphenyl-2-
picrylhydrazyl (DPPH) free radical scavenging and cupric reducing 
antioxidant capacity (CUPRAC) assays. In this assay, compound 73 
depicted highest absorbance (0.87) at 100 ppm as compared to 
standard gallic acid (1.4) and quercetin (1.2) at same concentration 
[44]. 1,2,4-(triazolo[3,4-b][1,3,4]thiadiazol-6-yl) selenopheno[2,3-
d]pyrimidine analogs were designed, synthesized and characterized 
Siddiqui et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 8-21 
16 
by Kotaiah et al., 2014 with substituted anilines and benzoic acids. 
The newly synthesized compounds were screened for antioxidant 
activity by DPPH, NO, and H2O2 radical scavenging methods. 
Compounds 74, 75 and 76 were found promising antioxidant 
molecules when compared with standard drugs Ascorbic acid and 
Butylated Hydroxy Toluene (12.27±0.86 and 16.53±1.74 
respectively) with the least values of IC50 11.02±0.27, 10.41±0.23 
and 9.46±0.91 μg ml-1, inhibition concentration respectively. The 
study shows indicates that these compounds were capable of 





Pyrimidines as antiparkinson agent 
Parkinson’s disease (PD) is a slowly progressive neurodegenerative 
disease, mainly characterized by the selective loss of dopaminergic 
neurons of the substantia nigra (SN), affecting the 1–2% of the 
general population over the age of 65. It has been suggested that 
neuroinflammation, oxidative stress, protein degradation, 
mitochondrial dysfunction, aging and disturbed autophagy are 
associated with this pathology [1]. Adenosine is a neuromodulator 
that coordinates responses to dopamine and other 
neurotransmitters that play important roles in motor function, 
mood, and memory. Selective A2A antagonists are a target for the 
symptomatic relief of PD, with some reports indicating that they 
may also slow disease progression because of their neuroprotective 
activity [46]. 
A novel series of benzyl substituted thieno [2,3-d]pyrimidines were 
identified as potent A2A receptor antagonists by Shook et al., 2013. 
Among the synthesized compounds, some of the compounds were 
screened for the ability to reverse cataleptic activity in mice. These 
compounds were typically tested as a single oral dose of 3 or 10 mg/kg 
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Pyrimidines as antiprotozoal agent 
Malaria, dysentery, leishmaniasis and human African 
trypanosomiasis are some diseases caused by parasitic protozoa and 
are major causes of death around the world. Thus, the study of 
effects of organic compounds on protozoa is need of the hour. 
Therefore, identification of new lead compounds is must, and 
inhibition of cellular kinase activity has been identified as a useful 
tool [47]. Leishmaniasis is a vector-borne parasitic disease which is 
caused by more than 20 species of protozoan Leishmania and it is 
transmitted by the bite of female phlebotomine sand flies. 
Leishmaniasis has been classified into these major clinical forms: 
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and 
mucocutaneous leishmaniasis (MCL) which differs in 
immunopathologies and degree of morbidity and mortality [48]. 
Suryawanshi et al., 2013 designed and synthesized a library of 
substituted aryl pyrimidine derivatives. All these compounds were 
screened in vitro by reporter gene luciferase assay for their 
antileishmanial property against intracellular amastigotes of 
Leishmania donovani. Among them, 8 compounds showed 
promising IC50 values (0.5 to 12.9 μM). Selectivity indices (S. I.) of all 
these compounds were found better than reference drugs, sodium 
stibogluconate (SSG) and miltefosine. These compounds were 
further screened for their in vivo antileishmanial activity against L. 
donovani/hamster model. Compounds 79, 80 and 81 have shown 
significant inhibition of parasitic multiplication (88.4%, 78.1% and 
78.2% respectively) at a daily dose of 50 mg/kg i. p. for 5 d. 
Compound 79 may be a new lead that could be explored as a new 
antileishmanial agent [48]. A library of classical antifolates, 2-amino-
4-oxo-5-substituted pyrrolo[2,3-d] pyrimidines have been designed, 
synthesized by Kumar et al., 2013. The synthesized compounds were 
evaluated for Cryptosporidium hominis thymidylate synthase (ChTS) 
inhibitory activity. Crystal structure of several hydrophobic, Van der 
Waals and hydrogen bonding interactions were studied between most 
potent compound 82 and FdUMP; compound 82 and active site 
residues, with a Ki of 8.83±0.67 nM. Therefore, compound 82 may be a 
lead compound for analog design and as ChTS specific inhibitors [49]. 
Kaspersen et al., 2012 designed, synthesized and evaluated 6-aryl-
pyrrolo [2,3-d]pyrimidine-4-amines for their antiprotozoal activity 
using Tetrahymena as the model organism. The protozoacidal activity 
results showed that compound 83, 84, 85, 86 and 87 were found to be 
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Pyrimidines as anti-thyroid agent 
Iodide translocation into thyroid cells is the rate-limiting step in the 
biosynthesis of iodinated hormones T3 and T4 and the process is 
mediated by the sodium iodide symporter (NIS), a glycoprotein with 
13 putative transmembrane domains. These are mainly expressed in 
the thyroid gland and some other tissues like salivary glands, gastric 
mucosa, and mammary glands during lactation. Several studies 
conclude the role of NIS in many thyroids as well as non-thyroid 
diseases like cancer (thyroid, breast), thyrotoxicosis and congenital 
hypothyroidism. Furthermore, the ability of NIS-expressing cells to 
take up iodide has provided a basis for extra-thyroid cancer cell 
destruction by radioiodine after the tumor-selective introduction of 
exogenous NIS [50]. 
Lacotee et al., 2013 synthesized a small library of dihydropyrimidin-
2-ones (DHPMs) using the multi-component Biginelli reaction, and 
the compounds were tested for their potential to block sodium 
iodide symporter (NIS) via using a cell-based assay. Compound 88 
showed most promising results (IC50 =65 pM). The study provides 












Pyrimidines as anti-tubercular agent 
Tuberculosis is a chronic infectious disease transmitted by cough-
propelled droplets that carry the disease carrying bacterium, 
Mycobacterium tuberculosis. Although currently available drugs kill 
most isolates of M. tuberculosis but strains resistant to each of these 
have emerged, and multiply resistant strains are increasingly 
widespread. The growing problem of drug resistance combined with a 
global incidence of several thousand of new cases per year and therefore, 
there is an urgent need for new antituberculosis therapies [51].  
Chikhale et al., 2015 designed synthesized and characterized 
derivatives of benzothiazolyl pyrimidine-5-carboxamides. These 
derivatives were synthesized by three component one pot reaction 
involving benzothiazolyl oxo butanamide, thiourea and substituted 
aromatic benzaldehydes. All of these derivatives were evaluated for 
antitubercular activity. Compound 89, 90, 91 and 92 were found 
active against Mycobacterium tuberculosis (H37Rv) with MIC= 0.08, 
0.09, 0.09 and 0.08 μM respectively and IC50 = 7.7±0.8, 9.2±1.5, 
11.1±1.8 and 10.3±2.6 respectively. Log P study of these compounds 
was found to be between 2.0 and 3.0 making them suitable for oral 
dosing. Furthermore, DprE1 selectivity and pharmacokinetic studies 
indicated that compound 89 and 92 were found to be highly 
selective, and bioavailability was found to be above 52% by oral 
dose [52]. Matyugina et al., 2012 synthesized a series of new 
carbocyclic uracil derivatives and tested for their antituberculosis 
potential. The results revealed that compound 6 showed best 
antituberculosis activity against two strains of Mycobacterium 
tuberculosis: laboratory sensitive (H37Rv) and MDR strain (MS-
115) resistant to five top antituberculosis drugs (isoniazid, 
rifampicin, streptomycin, ethambutol and pyrazinamide). The 
compound 93 showed the same level of antituberculosis activity 
both as a racemic mixture and individual (+) and (-) enantiomers 
[53]. Toti et al., 2013 synthesized some 50-modified thymidines and 
5,5’-bis-substituted 20-deoxyuridine analogs and screened them for 
inhibition potency of thymidine monophosphate kinase of 
Mycobacterium tuberculosis (TMPKmt) by using spectrophotometric 
binding assay (Ki). Compound 94 (Ki = 48 μM) and 95 (Ki = 70 μM) were 
found to be highly potent among all [54]. Shmalenyuk et al., 2013 
reported the synthesis of C5 modified pyrimidine nucleoside derivatives 
and screened them for their antituberculosis capacity. 5-
dodecyloxymethyl-2’-deoxyuridine (96), 5-decyl triazolidomethyl-2’-
deoxyuridine (97) and 5-dodecyltriazolidomethyl-2’-deoxycytidine (98) 
showed maximum in vitro inhibition of growth of Mycobacterium 
tuberculosis strains-laboratory H37Rv (MIC99 = 20, 10, and 20 μg/ml, 
respectively) and clinical MDR MS-115 resistant to five top 
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Pyrimidines as anti-viral agent 
Highly active antiretroviral therapy (HAART) is a treatment regimen 
for human immunodeficiency virus (HIV) infections, involving the co-
administration of nucleoside reverse transcriptase inhibitors (NRTI), 
non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease 
inhibitors. This therapy suppresses the replication of HIV and controls 
disease progression in HIV-positive patients. Unfortunately, a drastic 
increase in the number of patients with HIV infection/AIDS has failed 
to respond to the current antiretroviral therapeutics because of the 
emergence of drug-resistant HIV variants and adverse effects of the 
drug. With this in mind, therefore, there is a continuous need to 
develop novel anti-HIV drugs that are effective against drug-resistant 
viruses and produce no adverse effects [55]. 
A small library of 5, 6-dihydroxypyrimidines were synthesized and 
tested in vitro for their anti-HIV activity profile by Guo et al., 2012. 
Among the synthesized compound, 99 and 100 showed significant 
anti-HIV activity with EC50 values of 0.14 and 0.15 μM respectively, 
and TI (therapeutic index) values of>300 and>900, respectively. 
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Thus, the study results showed that 5,6-dihydroxypyrimidines may 
act as a lead compound for the discovery of potent anti-HIV agents 
as they showed decreased cytotoxicity with high therapeutic index 
[56]. Tremblay et al., 2013 demonstrated the synthesis of 
benzofurano[3,2-d]pyrimidine-2-one and tested the synthesized 
compounds for nucleotide-competing HIV-1 reverse transcriptase 
inhibitors (NcRTI) activity. Compound 101 exhibited promising 
overall in vitro properties as HIV-1 RT inhibitors. Therefore, it 
revealed the potential of benzofurano[3,2-d]pyrimidine-2-one 
derivatives as a class of future anti-HIV agent [57]. Tichy et al., 2012 
designed, synthesized and characterized a new set of pyrimido[4,5-
b]indole ribonucleosides derivatives and tested for biological 
activity for Dengue virus. Among all the compounds, 102 exhibited 
significant activity against Dengue virus with IC50 value 0.85 μm 
against Vero cells DENV-2 [58]. Mizuhara et al., 2012 identified the 
synthesis of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives as 
a potent antiretroviral agent. Among them, compound 103 and 104 
showed threefold higher anti-HIV activity than that of PD 404182 
[59]. 20,30-dideoxy-20,20-difluoro-40-azanucleoside derivatives of 
both pyrimidine and purine nucleobases were synthesized by 
Martínez-Montero et al., 2012 and evaluated them for their anti-HIV-
1 and anti-HCV activity. Among the series, 40-azanucleosides (105) 
was found to be the most active compound (EC50 = 36.9 μM) and 
none of the compounds were found to possess anti-HCV activity 
[60]. Two series of new 4-aminopyrimido[4,5-b]indole 
ribonucleoside derivatives were synthesized by Tichy et al., 2013. 
All of these compounds were tested for antiviral activities against 
HCV and dengue viruses. Compound 106 exhibited significant anti-
dengue and anti-HCV activity but with some level of cytotoxicity. 
Compound 107 showed high anti-HCV activity with low cytotoxicity 
[61]. Sakakibara et al., 2013 synthesized a library 3-(3,5-
dimethylbenzyl)uracil analogs and evaluated them for non-
nucleoside HIV-1 reverse transcriptase inhibition potential. Among 
these compounds, 108 was found to be potent against HIV-1 activity 
(EC50 =0.03 μM and a high selectivity index=2863). Thus, compound 
108 may serve as a lead for further optimization of anti-HIV drugs 
[62]. Rai et al., 2013 designed, synthesized and evaluated 3-
benzyloxy-linked pyrimidinyl phenyl amine derivatives for their in 
vitro anti-HIV activity in MT-4 cell cultures. Almost all the 
compounds showed inhibition of wild-type (wt) HIV-1 replication 
(EC50 = 0.05–35 μM) with high selectivity index (SI) values (10 
to>4870). Compounds 109 and 110 exhibited excellent 
antiretroviral activity against wt HIV-1 with low cytotoxicity (EC50 = 
0.07 μM, CC50>347 μM, SI>4870; EC50 = 0.05 μM, CC50 = 42 μM, SI = 
777, respectively), compared to marked drug nevirapine (EC50 = 
0.113 μM, CC50>15 μM, SI>133) [63]. Mohamed et al., 2010 designed, 
synthesized and evaluated some substituted pyrimidine derivatives 
for their anti-HSV-1 potential. The antiviral screening exhibited that 
compounds 111 and 112 have over 90% inhibition comparable to 
standard Acyclovir. These compounds may be considered highly 
promising antiviral agent for further investigations [64]. Kim et al., 
2013 identified a series of triazolothieno pyrimidine (TTPM) 
compounds as potent HIV-1 replication inhibitors. By performing a 
cell-based full replication assay, it was found that aryl substituted 
TTPM derivatives 113, 114, and 115 showed significant inhibitory 
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Pyrimidines as human urea transport protein (ut-b) inhibitor 
For the formation of concentrated urine Kidney urea transporters 
(UTs) are required. In some kidney tubules, epithelial cells express 
UT-A proteins which are encoded by the SLc14A2 gene, and 
endothelial cells in some microvessels express UT-B encoded by the 
SLc14A1 gene. Early high-throughput screening using a human 
erythrocyte lysis assay identified phenyl-sulfoxyoxozole inhibitors 
of human UT-B with IC50=100 nM. Limitations of the original 
compounds included poor metabolic stability and poor activity 
against rodent UT-B. Therefore, for the development of UT-B 
inhibitors further studies are needed to be done [66]. 
Liu et al., 2013 designed and synthesized some analogs of the UT-B 
inhibitor on the basis of already synthesized 
triazolothienopyrimidine derivatives which were reported as UT-B 
inhibitors. All the synthesized compounds were characterized by the 
structural requirements for potency and microsomal stability to 
behave a compound as UT-B inhibitor scaffold. Two compounds 116 
and 117 with nanomolar inhibitory potency (IC50 = 40 nM) were 
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Pyrimidines as immunosuppressant agent 
The major problem in organ transplantation is suppression of 
allograft rejection. In last few years, the patient and graft survival is 
increased dramatically, due to the availability of improvement in 
immunosuppressive therapy. Current immunosuppressive regimens 
involve a combination of a calcineurin inhibitor (cyclosporine or 
tacrolimus), a glucocorticoid (prednisone), an antiproliferative agent 
(azathioprine or mycophenolate) and a new combination (sirolimus 
and everolimus). Both compounds inhibit a kinase, called the 
mammalian target of rapamycin (mTOR). These current 
immunosuppressive drugs are effective for the inhibition of T-
lymphocyte dependent rejection but are quite ineffective in preventing 
or treating chronic rejection. Almost all of these drugs show toxicities 
that impair patient and graft survival. So, there is a continuous need 
for the search of novel immunosuppressive agents [67]. 
Stella et al., 2013 synthesized a novel class of pyrimidine derivatives 
and screened them for immunosuppressive activity by using the 
Mixed Lymphocyte Reaction assay. This is also called as the in vitro 
model for in vivo rejection after organ transplantation. By 
replacement of the substituents at positions 2, 4 and 6 of the 
pyrimidine scaffold resulted in the discovery of 2-benzylthio-5-
cyano-6-(4-methoxyphenyl)-4-morpholinopyrimidine 118 which 
can be used for further optimization of more efficient 
immunosuppressive drugs. The IC50 value of this compound was 













This study brings to light the pyrimidine derivatives and their 
diverse potential in drug development and medicine. It is evident 
that pyrimidine derivatives have been investigated for a number of 
ailments as highlighted in this review. As pyrimidines are the 
structural constituent of vital biomolecules like DNA and some 
biologically relevant drugs. Therefore, pyrimidine derivatives are 
gaining attention as antimicrobial, anticancer, antiviral, 
anticonvulsant agents, etc. Furthermore, due to the resistance of 
currently available drugs, there is a strong need to pursue further 
research on pyrimidines.  
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